What is the success rate for Carvykti?

Official answer

by Drugs.com

In the CARTITUDE-1 study, 95 of 97 of patients with relapsed or refractory multiple myeloma (bone marrow cancer) responded to Carvykti after one infusion for an overall response rate of 98%.

Relapsed cancer is cancer that has come back and refractory cancer has stopped responding to treatment.

In this study, overall response rate (ORR) was defined as the total number of patients who had a stringent complete response, very good partial response and partial response to therapy.

76 of 97 people (78%) experienced a stringent complete response (sCR), which was the best possible response a participant could have towards treatment. A sCR is when your doctor is unable to observe any signs or symptoms of cancer via imaging or other tests after treatment.

16 of 97 people (17%) experienced a very good partial response (VGPR).

3 of 97 people (3%) experienced a partial response (PR).

How fast does Carvykti work?

The median time to reach a first response was one month after the Carvykti infusion, but this ranged from 0.9 months to 10.7 months.

A median time of one month means that one half of patients responded before one month, and one half responded later than one month, after treatment was given.

What does Carvykti treat?

In February 2022, the FDA approved Carvykti (generic name: ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM), a cancer of the bone marrow.

It’s used after you have received 4 or more previous treatments and your cancer came back or you stopped responding.

Previous treatments include at least one medicine from each of these 3 drug classes: a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Carvykti is manufactured by Janssen Pharmaceuticals.

How long will Carvykti work for multiple myeloma?

In a clinical research study, half of the people treated with Carvykti kept responding to treatment for at least 21.8 months (the median duration of response).

In the 78% of patients who originally had the best possible response to Carvykti treatment (stringent complete response or sCR), the median duration of response was not yet met at 18 months of follow up. This means that more than 50% of patients in this group were still responding 18 months after treatment.

How does it work?

Carvykti is known as CAR-T cell therapy and works by using your own white blood cells (called T cells) to attack and kill the cancer.

CAR-T stands for “chimeric antigen receptor T” cell. T cells travel throughout our body looking for cancer cells, but sometimes the cancer develops a way to prevent the T cell from recognizing and killing it. Carvykti looks for special proteins found on the surface of the multiple myeloma cancer cell and normal plasma cells.

Carvykti is made by collecting your T cells from your blood and modifying them to create CAR-T cells, which you will then receive through a one-time infusion back into your body. These personalized CAR-T cells can grow in your body and are better able to find the cancer and help fight it.

Related: Carvykti side effects (in detail)

This is not all the information you need to know about Carvykti (ciltacabtagene autoleucel) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.